microRNA Replacement Therapy
Management

Mirna has assembled an experienced management team with leaders in microRNA and cancer research, and all aspects of drug and business development.

Mirna-Michael Powell
Dr. Paul Lammers has served as a member of Mirna’s board of directors and as President and Chief Executive Officer since November 2009. Previously, Dr. Lammers was the President of Repros Therapeutics Inc., a biopharmaceutical company. Dr. Lammers has also served as the Chief Medical Officer for EMD Serono, Inc., a biopharmaceutical division of Merck KGaA, Senior Vice President of clinical and regulatory affairs at Zonagen, Inc., which later became Repros Therapeutics, and Organon International, a pharmaceutical company, spending eight years in the commercial and clinical operations in Europe and the United States. Dr. Lammers received an M.Sc. and M.D. from the Catholic University (Radboud University) in Nijmegen, The Netherlands.
Dr. O’Neill has served as Chief Medical Officer since April 2016. He previously served as the Chief Medical Officer of Exosome Diagnostics, a healthcare company. Dr. O’Neill has also served as the Global Head of Personalized Medicine and Companion Diagnostics at Sanofi S.A., a multinational pharmaceutical company. Previously, Dr. O’Neill was a Group Director at Genentech, Inc. Dr. O’Neill has also served at GlaxoSmithKline, Beatson Oncology Centre, F. Hoffmann La-Roche and the University of Glasgow. Dr. O’Neill received his M.D., and his B.Sc. in molecular pathology, from the University of Glasgow. He is also a member of the Royal College of Physicians.
Mirna-Michael Powell
Ms. Casi DeYoung joined Mirna Therapeutics in March 2014 as Chief Business Officer. Prior to Mirna, Ms. DeYoung served as Vice President of Business Development at Reata Pharmaceuticals. Previously, Ms. DeYoung served as the Vice President of Business Development for ODC Therapy, Inc., an immunotherapy company. Ms. DeYoung has also served in various commercial and business development roles, including Director of Global Oncology Operations for EMD Pharmaceuticals, Inc., the U.S. affiliate of Merck KGaA. Ms. DeYoung received a bachelor’s degree in chemistry from Southwestern University and an M.B.A. from the University of Texas at Austin.
Mirna-Michael Powell
Alan Fuhrman has served as our Chief Financial Officer since September 2015. Mr. Fuhrman previously served as the Chief Financial Officer of Ambit Biosciences Corporation, a biopharmaceutical company, including through the company’s initial public offering in 2013 and until its sale to Daiichi Sankyo for up to $410 million. Prior to this role, Mr. Fuhrman served as Chief Financial Officer of Naviscan, Inc., a privately held medical imaging company and as Chief Financial Officer of Sonus Pharmaceuticals, Inc., a pharmaceutical company. Mr. Fuhrman is a member of the board of directors of Loxo Oncology, Inc. Earlier in Mr. Fuhrman’s career he practiced as a CPA with Coopers and Lybrand. Mr. Fuhrman received a B.S. in both Business Administration and Agricultural Economics from Montana State University.
Mirna-Michael Powell
Dr. Stoudemire is the Vice President, Preclinical Development, Regulatory & Quality Assurance at Mirna Therapeutics. Prior to joining Mirna in 2010, he has held positions at Genentech, Ascenta Therapeutics, Chugai-Roche Pharmaceuticals, Cytel, Genetics Institute, and Xoma, with responsibility for the pharmacokinetic and toxicological evaluations of a range of small molecules and biologics, including cytokines, growth and hematopoietic factors, monoclonal antibodies and pro-apoptotic therapeutics. Dr. Stoudemire received his Ph.D. in microbiology from the University of Miami and completed a postdoctoral fellowship in the Cardiovascular Research Institute at the University of California San Francisco.
© 2015 Mirna Therapeutics, Inc. All Rights Reserved.